EUnetHTA

The European network for Health Technology Assessment EUnetHTA was established to create an effective and sustainable network for HTA across Europe. Its purpose is to help develop reliable, timely, transparent and transferable information that contribute to HTAs in European countries. EUnetHTA supports collaboration between European HTA organisations that bring added value at the European, national and regional level through facilitating efficient use of resources available for HTA, creating a sustainable system of HTA knowledge sharing and promoting good practice in HTA methods and processes.


Outputs

EUnetHTA Guidelines The primary aim of the guidelines is to help the assessors of evidence to process, analyse and interpret the data. The links to all published EUnetHTA methodological guidelines can be found below: Read more Tools EunetHTA has developed several tools to support the conduciton of Joint Assessments, but […]


Publication of final project plan of the assessment on “Relative effectiveness assessment of Femtosecond laser-assisted cataract surgery (FLACS) compared to standard cataract surgery”

Relative effectiveness assessment of Femtosecond laser-assisted cataract surgery (FLACS) compared to standard cataract surgery The publication of the final project plan of the assessment on “Relative effectiveness assessment of Femtosecond laser-assisted cataract surgery (FLACS) compared to standard cataract surgery” and the comments provided by one manufacturer during fact check of […]


Proposed Regulation on HTA in Europe

WP1 Lead Partner, in its function as the EUnetHTA Directorate, acknowledges the recent publication of the proposed Regulation on HTA in Europe. The EUnetHTA JA3 Directorate looks forward to constructive dialogue vis-à-vis the proposed Regulation and continues to actively support HTA collaboration in Europe through Joint Action 3.


Call for Comments – ATMP guideline on safety and efficacy follow-up and risk management

The revised ATMP guideline on safety and efficacy follow-up and risk management has been released for a 3-month public consultation (deadline of 30th April). EMA would be pleased to receive any HTA comments in respect of the post-authorisation safety and efficacy studies’ endpoints. Please see the links below. http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2018/02/news_detail_002897.jsp&mid=WC0b01ac058004d5c1 Guideline […]


WP4 PTJA03 on “Alectinib (Alecensa©) as monotherapy for the first line treatment of adult patients with ALK-positive advanced non-small cell lung cancer (NSCLC)” is now available

This is the assessment of the relative effectiveness of “Alectinib (Alecensa©) as monotherapy for the first line treatment of adult patients with ALK-positive advanced non-small cell lung cancer (NSCLC). We are pleased to announce that the pharmaceutical Joint Rapid Assessment on “Alectinib (Alecensa©) as monotherapy for the first line treatment […]


Final assessment report on MammaPrint® – Added value of using the gene expression signature test MammaPrint® for adjuvant chemotherapy decision-making in early breast cancer

2018 – PDF . Final Assessment Report, External Comments/Answers and Project Plan for Other Technologies CA MammaPrint® This is the assessment of the relative effectiveness of MammaPrint® – Added value of using the gene expression signature test MammaPrint® for adjuvant chemotherapy decision-making in early breast cancer. Find the documentation provided […]


An analysis of HTA and reimbursement procedures in EUnetHTA partner countries: final report

An analysis of HTA and reimbursement procedures in EUnetHTA partner countries: final report Background Health technology assessment (HTA) is the systematic evaluation of properties, effects, and/or impacts of health technologies. HTA aims to respond to decisionmakers’ information needs regarding the introduction, coverage, use or disinvestment of health technologies. Information needs […]


EMA and EUnetHTA finalise joint work plan for 2017-2020

Medicines regulator and network of Health Technology Assessment (HTA) bodies continue to strengthen their collaboration The European Medicines Agency (EMA) and the European Network for Health Technology Assessment (EUnetHTA) have published a joint work plan outlining key areas of collaboration for the next three years. The EMA-EUnetHTA collaboration, which began […]


MammaPrint® – Added value of using gene-expression signature for adjuvant chemotherapy decisions in early breast cancer assessment (OTCA04)

Final project plan for Other Technologies CA on MammaPrint® – Added value of using gene-expression signature for adjuvant chemotherapy decisions in early breast cancer assessment (OTCA04) This is the final project plan of the Other Technologies CA on MammaPrint® – Added value of using gene-expression signature for adjuvant chemotherapy decisions […]


WP4 PTJA02 on “Regorafenib (Stivarga©) indicated as monotherapy for the treatment of adult patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib” is now available

Final Assessment Report, External Comments/Answers and Project Plan for pharma JA on Regorafenib (Stivarga©) We are pleased to announce that the pharmaceutical Joint Rapid Assessment on “Regorafenib (Stivarga©) indicated as monotherapy for the treatment of adult patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib” is now […]